Navigation Links
Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
Date:10/26/2008

Iclaprim also achieved high eradication rates for the most common pathogens, including methicillin-resistant Staphylococcus aureus (MRSA)

REINACH, Switzerland, Oct. 26 /PRNewswire-FirstCall/ -- Arpida (SWX: ARPN) today presented the combined results from two pivotal Phase III clinical trials at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, DC. In these studies, intravenous iclaprim, a novel antibiotic, showed high clinical cure rates which were similar to those of the comparator drug, linezolid, in the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). In addition, iclaprim was well-tolerated with a safety profile that compared favorably to linezolid. A New Drug Application for intravenous iclaprim in cSSSI will be discussed at the meeting of the U.S. Food and Drug Administration Anti-Infective Drugs Advisory Committee on 20 November 2008.

Iclaprim, a novel antibiotic from the trusted dihydrofolate reductase (DHFR) selective inhibitor class of antibiotics, was specifically designed to address the growing need for additional treatment options to combat resistant infections including MRSA. MRSA affects more than 2 million people in the United States each year and rates of hospital- and community-acquired MRSA are on the rise.(i,ii)

"The high efficacy rates and favorable tolerability profile of iclaprim strongly supports its potential as a new treatment option for patients who have acquired serious infections caused by MRSA," said Dennis L. Stevens, MD, PhD, Veterans Affairs Medical Center, Boise, Idaho. "With rates of MRSA increasing and effectiveness of some current antibiotics declining, it is important to identify effective alternative treatments for these infections."

The results presented at the ICAA
'/>"/>

SOURCE Arpida
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... LAS VEGAS , July 25, 2014 GrowBLOX ... of a binding Memorandum of Understanding ("MOU") with LaurelCo, LLC, ... to pursue the acquisition of both cultivation and dispensary medical ... . Pursuant to the MOU, GBLX will acquire a 20% ... use our proprietary GrowBLOX TM growing chambers, as well ...
(Date:7/25/2014)...  Acsis Inc., the market leader for supply ... recently posted an article, "Future of Running ... needs for companies, extended supply chain, and explains ... no longer work today.  The article explains how ... mobile technology, machine to machine (M2M) connectivity, and ...
(Date:7/25/2014)... MEXICO CITY , July 25, 2014 ... a Latin American healthcare sciences publisher, launched a library ... on conditions such as cancer and heart disease. Healthcare ... most up-to-date information to deliver better patient care. ... rapidly, with many relying on smartphones and tablets to ...
Breaking Medicine Technology:GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Acsis Addresses Questions on the Modern Supply Chain 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4
... Pfizer Inc. has agreed to provide the University ... set of electrocardiographic data that will help researchers develop ... This is the first time a major pharmaceutical ... one of its drug safety trials, including data from ...
... Mass., Jan. 12 Solace Pharmaceuticals, a,private ... pain, announced the initiation of a proof-of-concept ... neuralgia (PHN). PHN, a painful,complication of shingles, ... the,US alone. The clinical trial is an ...
Cached Medicine Technology:Pfizer Contributes Critical Data to URMC Drug Safety Initiative 2Pfizer Contributes Critical Data to URMC Drug Safety Initiative 3Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 The American ... new volunteer network “ABTA CommYOUnity™” during its annual patient ... pivotal time for the brain tumor community as we ... patient and caregiver support services and funding brain tumor ... are passionate about brain tumor awareness and getting our ...
(Date:7/25/2014)... IL (PRWEB) July 25, 2014 There are ... and 500 diagnosed each day. Though when someone hears the ... confused and are unsure of the next step and where ... helping people figure out that next step by providing and ... this more than Brian Olson, member of the ABTA’s Board ...
(Date:7/25/2014)... Progress in understanding the molecular genetics of ... promising brain tumor treatments, according to Patrick Wen, MD, ... Center for Neuro-Oncology, Dana-Farber Cancer Institute. , At the ... Conference in Chicago, July 25-26, Dr. Wen will moderate ... impacting the development of new treatments and advancing strategies ...
(Date:7/25/2014)... According to the new report "Sapphire Technology Market by ... Analysis & Forecast to 2013 - 2020", the global ... Billion by 2020 at a CAGR of 12.31%, whereas ... to reach $6.17 billion by 2020 at a CAGR ... and geography. , Browse more than 65 market data ...
(Date:7/25/2014)... CA (PRWEB) July 25, 2014 Splashtop, ... WorkPlace Partner Program . Splashtop Business and Splashtop Enterprise ... and will leverage the MaaS360 WorkPlace SDK to ... , Splashtop Business and Splashtop Enterprise offer secure remote ... device. High performance, ease of use, collaborative ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 2Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 6Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 2Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 3Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 4
... With audience members cheering and,famous Chicago chefs watching ... for the finalists at Consorta,s Battle of the Hospital,Chefs. ... the organic cucumbers he,serves the patients at Saint Mary,s ... event,s Gold Chef Award, becoming the reigning champion of,chefs ...
... systemic fibrosis (NSF) is a newly identified debilitating and ... is characterized by a thickening and hardening of the ... it can also affect internal organs and can progress ... within a few weeks. Although it is not clear ...
... and problems in ones neighborhood are associated with greater ... in Vancouver, Canada. , Social environment has long been ... in youth, but few studies have empirically tested social ... their implications for childhood asthma. , Edith Chen, Ph.D., ...
... PHOENIX, Sept. 27 Matrixx Initiatives, Inc.,(Nasdaq: ... and,markets products that provide consumers with "Better Ways ... 3, 2007, at the,William Blair & Company Small-Cap ... presenting at 3:20 p.m. ET. To listen to ...
... for the pub musicians who play them, Irish researchers say ... is not only salve for the lungs, it is music to ... air quality in Irish pubs as well as the health of ... play them, research suggests. , "Research to date looking at ...
... Non Media types, its,hard not to notice that Britney has been ... something is definitely going on with our,Famed Star. On a ... makeover and when asked what type of smile she wanted, she ... celebrity stars and right,on top of that pile was ... you ...
Cached Medicine News:Health News:National Battle of the Hospital Chefs Cooks Up a Winner 2Health News:Higher death rates in kidney patients with newly recognized disease 2Health News:Higher death rates in kidney patients with newly recognized disease 3Health News:Dysfunctional families and bad neighborhoods may worsen asthma in children and adolescents 2Health News:Dysfunctional families and bad neighborhoods may worsen asthma in children and adolescents 3Health News:Matrixx Initiatives, Inc. to Present at the William Blair & Company Small-Cap Growth Stock Conference 2Health News:Accordions Breathe Easier Since Smoking Ban 2
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: